[Scleromyxedema: immunosuppressive therapy with cyclophosphamide].
A 59-year-old male with scleromyxedema showed lichenoid papules over the large joints and buttocks; excessive skin folds, and generalized sclerosis of the skin similar to scleroderma; myopathy and arthritis; cardiovascular and cerebrovascular disease; and an abnormal monoclonal IgG-type protein in the serum. The progression of the disease, lack of established therapeutic modalities and the pronounced systemic involvement in this condition suggested a therapeutic trial employing monthly high-dose i.v. cyclophosphamide pulse therapy, together with low-dose prednisone on alternate days. The results were excellent and both subjective and objective symptoms improved dramatically. Controls performed at regular time intervals during a follow-up period of 12 months have failed to reveal any recurrence of the disease.
Aberer
W
W
I. Universitäts-Hautklinik Wien.
Wolff
K
K
D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D009230:Myxedema / Q000150:complications / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*
D003520:Cyclophosphamide; D011241:Prednisone
Skleromyxödem: immunsuppressive Therapie mit Zyklophosphamid.